Global clinical trials activity decreased by 2.9% in Q2 2020, when compared with the same quarter in 2019, according to GlobalData.
Industry-sponsored trials accounted for a 46.1% share of overall activity in Q2 2020, an increase of 1.3% when compared with Q2 2019.
Go deeper with GlobalData
Non-industry-sponsored trials accounted for a 53.9% share of all clinical trials in Q2 2020, marking a decrease of 1.3% when compared with the same period in 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Q2 2020 industry-sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry-sponsored clinical trials in Q2 2020, accounting for a 28.3% share of all trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis was followed by infectious disease with a 25.8% share, central nervous system with 10.8%, respiratory with 9.6% and metabolic disorders with 6.6%.
In Q2 2019, oncology led with a 27.9% share, followed by central nervous system with 14.4%, infectious disease with 10.1%, metabolic disorders with 9.4%, and cardiovascular with 8.6%.
| Industry-sponsored trials: Q2 2020 vs Q2 2019 | |||
|---|---|---|---|
| Therapy Area | Q2 2019 | Q2 2020 | Activity |
| Oncology | 27.9% | 28.3% |  |
| Infectious Disease | 10.1% | 25.8% | |
| Central Nervous System | 14.4% | 10.8% |  |
| Respiratory | 5.5% | 9.6% | |
| Metabolic Disorders | 9.4% | 6.6% | |
| Cardiovascular | 8.6% | 6.0% | |
| Gastrointestinal | 7.0% | 5.5% | |
| Immunology | 5.9% | 4.9% | |
| Dermatology | 4.9% | 4.1% | |
| Genito Urinary System And Sex Hormones | 2.7% | 2.7% | |
| Musculoskeletal Disorders | 5.3% | 2.7% | |
| Hematological Disorders | 3.6% | 2.6% | |
| Ophthalmology | 3.0% | 2.5% | |
| Women’s Health | 2.4% | 1.7% | |
| Genetic Disorders | 1.7% | 1.6% | |
| Male Health | 0.6% | 1.0% | |
| Ear Nose Throat Disorders | 1.1% | 0.9% | |
| Hormonal Disorders | 0.8% | 0.4% | |
| Mouth and Dental Disorders | 0.7% | 0.4% | |
| Non Malignant Disorders | 0.3% | 0.2% | |
| Nutritional Disorders | 0.7% | 0.2% | |
Most active therapy areas in non-industry-sponsored clinical trials
In Q2 2020 the leading therapy area for non-industry-sponsored clinical trials was infectious disease, accounting for a 34.9% share of all trials.
This was followed by oncology with a 20.0% share, central nervous system with 16.3%, respiratory with 10.1%, and cardiovascular with 7.0%.
In Q2 2019, central nervous system held the lead in non-industry-sponsored clinical trials with a 26.0% share, followed by oncology with 19.8%, cardiovascular with 9.6%, metabolic disorders with 7.8%, and gastrointestinal with 7.7%.
| Non-Industry-sponsored trials: Q2 2020 vs Q2 2019 | |||
|---|---|---|---|
| Therapy Area | Q2 2019 | Q2 2020 | Activity |
| Infectious Disease | 7.3% | 34.9% | |
| Oncology | 19.8% | 20.0% | |
| Central Nervous System | 26.0% | 16.3% | |
| Respiratory | 3.9% | 10.1% | |
| Cardiovascular | 9.6% | 7.0% | |
| Gastrointestinal | 7.7% | 5.4% | |
| Metabolic Disorders | 7.8% | 4.1% | |
| Women’s Health | 6.3% | 4.0% | |
| Musculoskeletal Disorders | 5.7% | 3.6% | |
| Immunology | 2.9% | 2.9% | |
| Hematological Disorders | 3.3% | 2.7% | |
| Genito Urinary System And Sex Hormones | 3.6% | 2.2% | |
| Dermatology | 3.2% | 2.1% | |
| Mouth and Dental Disorders | 2.6% | 1.4% | |
| Ear Nose Throat Disorders | 1.4% | 1.1% | |
| Ophthalmology | 2.0% | 1.1% | |
| Genetic Disorders | 0.7% | 0.7% | |
| Nutritional Disorders | 0.7% | 0.5% | |
| Male Health | 1.0% | 0.4% | |
| Hormonal Disorders | 1.2% | 0.3% | |
| Non Malignant Disorders | 0.5% | 0.3% | |
Asia-Pacific region has the most activity for industry-sponsored clinical trials
Asia-Pacific was the most active region for industry-sponsored clinical trials activity in Q2 2020 with a 47.9% share, compared with 52.0% in Q2 2019.
North America was the second most active region with a 34.7% share in Q2 2020, up from 33.3% in Q2 2019, followed by Europe with a 28.0% share in Q2 2020, down from 29.2% in Q2 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 85.4% share in industry-sponsored clinical trials in Q2 2020, compared with 84.1% in Q2 2019. Multinational trials accounted for 14.6% in Q2 2020, against 15.9% in Q2 2019.
Regional activity for non-industry-sponsored clinical trials
Asia-Pacific saw the most non-industry-sponsored clinical trial activity in Q2 2020 with a 41.0% share, down from 54.4% in Q2 2019.
Middle East and Africa held the second position with a 19.9% share in Q2 2020, compared with 16.1% in Q2 2019. This was followed by North America with a 19.9% share in Q2 2020, as against 16.4% in Q2 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies accounted for 98.8% share of non-industry-sponsored clinical trials in Q2 2020, compared with 98.9% in Q2 2019. Multinational trials accounted for a 1.2% share in Q2 2020, up from 1.1% in Q2 2019.
Clinical trials by phase in Q2 2020
Phase II trials outnumbered all other studies with a 39.5% share for industry-sponsored trials in Q2 2020, compared with 33.8% in Q2 2019.
The share of Phase I trials stood at 30.0% in Q2 2020, down from 37.2% in Q2 2019. Phase III trials increased to 20.0% in Q2 2020, compared with 17.2% in Q2 2019, followed by Phase IV trials with a 10.5% share in Q2 2020, against 11.8% in Q2 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
For non-industry-sponsored clinical trials, Phase II activity decreased to a 43.7% share in Q2 2020, compared with 47.7% in Q2 2019.
Phase III trials were the second most active with a 23.8% share in Q2 2020, compared with 18.7% in Q2 2019. Phase IV trials held an 18.1% share in Q2 2020, against 19.5% in Q2 2019, followed by Phase I trials with a 14.5% share in Q2 2020, over 14.1% in Q2 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
